Comparative Daily Costs for Commonly used Comparative Daily Costs for Commonly Commonly used INTRAVENOUS INTRAVENOUS used ORAL * Antibiotics* Antibiotics*

Daily Med Daily Med Intravenous Antibiotics Normal Dose Cost ($) Oral Antibiotics Normal Dose Cost ($) P.O. Box 342 NOTES: Pencillins 1 gm q 6h 5.68 500 mg tid 0.24 This report summarizes routinely tested antibiotics. Minneapolis, MN 55440-0342 Ampicillin/ 3 gm q 6h 14.73 Amoxicillin/Clavulanate 500 mg tid 0.90 Actual patient reports may selectively exclude some 612-863-4678 1 gm q 4h 19.02 500 mg qid 2.84 susceptibility results. G 5 MU q 4h 45.18 Penicillin VK 500 mg qid 0.75 / 3.375 gm q8h 6.54 2020 Cephalosporins 500 mg bid 0.71 1 gm q 8h 1.98 300 mg bid 2.64 Regional Hospitals 1 gm q 8h 12.94 axetil 250 mg bid 2.90 Antimicrobial Susceptibilities 1 gm q 8h 9.05 Cephalexin 500 mg qid 0.30 Ceftazidime/ 2.5 gm q 8h 1075.89 Anaerobic of Major Pathogens 1 gm q 6h 11.18 Clindamycin 450 mg tid 1.80 Ceftaroline 600 mg q12h 315.62 Metronidazole 500 mg tid 0.46 Data is also located on the Allina Knowledge Network (AKN): Ceftolozane-tazobactam 1.5 gm q 8h 349.83 Miscellaneous Cefriaxone 1 gm q 24h 1.20 Acyclovir 200 mg 5x/d 0.55 http://labs.allinahealth.org/Lab/Linkview?Sublink=susceptdata Cefuroxime 1.5 gm q 8h 11.16 Atovaquone 1500 mg daily 40.38 Azithromycin 250 mg daily 0.66 1 gm q 24h 54.86 Ciprofloxacin 500 mg bid 0.26 The intent of this card is to provide a preliminary guide to 500 mg q 8h 29.82 Clarithromycin 500 mg bid 1.55 susceptibilities. This information should be used together with the 1 gm q 8 h 16.20 Dapsone 100 mg daily 0.65 Meropenem-vaborbactam 4 gm q 8h 945.96 Doxycycline 100 mg bid 0.37 specific susceptibility results of the isolated organism and guidelines from current publications. Aminoglycosides Erythromycin ethylsuccinate 400 mg qid 34.01 Gentamicin ⃰ 100 mg 2.53 Fluconazole 100 mg daily 0.96 Tobramycin⃰ (usual dose 5-7 mg/kg Results are from inpatients only and include only one isolate per q 24h or 1.8 mg/kg q 8h) 100 mg 0.97 1 packet x 1 85.00 patient. Anaerobic Agents Isavuconazonium Sulfate 372 mg daily 177.52 Clindamycin 900 mg q 8 h 16.09 Levofloxacin 750 mg daily 0.40 MRSA and VRE surveillance culture isolates are not included. Metronidazole 500 mg q 8 h 2.94 Linezolid 600 mg q 12h 6.44 Miscellaneous Moxifloxacin 400 mg q 24h 2.67 All intermediate (I) interpretations are included in the resistant Acyclovir 500 mg q 8 h 8.10 Minocycline 100 mg bid 0.89 category. Ambisome (usual 0.25-6 g/kg/day) 50 mg 99.10 Nitrofurantoin 100 mg bid 2.00 Azithromycin 500 mg q 24 h 2.37 Nitrofurantoin Suspension 50 mg bid 276.73 All organisms identified are held for a period of 7 days after the 1 gm q 8h 75.52 Posaconazole DR Tablets 300 mg daily 68.93 final results have been reported, in case further testing is Caspofungin 50 mg q 24h 57.60 Posaconazole Suspension 200 mg tid 191.52 Ciprofloxacin 400 mg q 12h 4.02 Rifaximin 550 mg bid 85.60 requested. Blood culture isolates are held for 1 month. Testing of (usual 4-6 mg/kg/day) 350 mg vial 22.84 Sulfa/Trimethoprim DS 1 tab bid 0.28 additional antimicrobials is available upon request. Doxycycline 100 mg q 12h 27.02 Capsule 125 mg qid 13.37 Erythromycin 500 mg q 6h 286.09 Vancomycin oral solution 125 mg qid 1.32 For further information, contact: Fluconazole 200 mg q 24h 3.73 Voriconazole 200 mg q 12h 11.94 Brenda Katz, MD, Pathologist, Isavuconazonium Sulfate 372 mg daily 302.07 [email protected], 612-863-4708 Levofloxacin 500 mg q 24h 1.87 Linezolid 600 mg q 12h 40.98 Costs as of January 2021. Subject to change. Moxifloxacin 400 mg q 24h 27.43 *The doses listed above and at left may need to be altered Ortavancin 1200 mg 2775 Posaconazole 300 mg daily 493.96 based on the type of and patient-specific Sulfa/Trimethoprim 10 ml q 8h 21.88 pharmacokinetics, including renal function in the case of Tigecycline 50 mg q 12h 106.24 INTRAVENOUS antibiotics. Vancomycin 1 gm q 12h 5.12 Voriconazole (usual 4 mg/kg q12h) 200 mg 22.35 Costs as of January 2021. Subject to change.

REGIONAL HOSPITALS-2020 ANTIMICROBIAL SUSCEPTIBILITIES

faecalis coagulase coagulase GRAM NEGATIVE BACILLI aeruginosa GRAM NEGATIVE BACILLI GRAM POSITIVE COCCI Percent Susceptible Percent Susceptible Percent Susceptible negative Escherichia coli Proteus mirabilis Klebsiella oxytoca Klebsiella variicola Citrobacter species Citrobacter Serratia marcescens Serratia Klebsiella aerogenes Klebsiella Enterobacter species Enterobacter Enterococcus Enterococcus Enterococcus faecium Enterococcus Streptococcus Group B Group Streptococcus Staphylococcus aureus Staphylococcus Pseudomonas Pseudomonas Staphylococcus Staphylococcus 115 149 2502 45 92 369 67 160 40 lugdunensis Staphylococcus Number of isolates Number of isolates 211 Number of isolates 407 221 692 385 100 48 - - 63 91 Ampicillin Ceftazidime 95 - 72 55 89 - *U 93 *U 96 *U 99 CLSI -1 Gentamicin 97 *NA *NA *NA Penicillin - - - - 100 Cefazolin ------CLSI -1 *NA *NA *NA Tobramycin 100 Cefazolin - 72 55 89 - 97 100 95 100 98 97 100 95 100 Gentamicin Cefepime 95 CLSI -1 Erythromycin - 58 47 84 48 Imipenem 96 Tobramycin 97 100 95 100 97 98 100 96 100 Clindamycin - 81 72 84 56 91 98 82 100 95 92 97 87 100 CLSI -2 Levofloxacin 85 Trimethoprim/sulfa - 94 78 100 - Trimethoprim/sulfa

- - 69 62 88 95 95 Ciprofloxacin 91 Ampicillin 99.8 451 - - - 100 Ampicillin/sulbactam Piperacillin/tazobactam 94 - - - - 100 Piperacillin/tazobactam 91 86 97 82 91 97 99 100

100 97 96 100 96 98 100 99 97 Tetracycline - 91 84 99 - Cefepime Guide for Clinical and Laboratory Standards Institute CLSI -2 CLSI -2 Vancomycin 99.5 771 100 100 100 100 86 83 95 82 92 97 100 99 92 (CLSI) groupings: Ceftriaxone CLSI -1 First choice drugs for treatment Rifampin (note A) - 99.6 - - - CLSI -2 Second choice drugs Ciprofloxacin 96 98 84 98 97 95 95 85 97 CLSI -3 For treatment of patients allergic Linezolid (note B) 100 1001 100 - - - 94 97 83 98 97 94 95 86 97 to primary drugs, treatment of Levofloxacin unusual organisms, or if institution Levofloxacin - 78 77 100 - 99 94 100 88 100 100 100 16 harbors endemic resistant strains. CLSI -3 Imipenem CLSI -4 For urinary tract only. Gentamicin - 99 97 100 - 87 85 95 82 96 97 100 99 97 CLSI -3 Ceftazidime Nitrofurantoin 99 311 981 991 - - 86 33 98 13 87 28 63 CLSI -4 CLSI -4 Nitrofurantoin Levofloxacin 83 501 - - - -

*U-Urine for uncomplicated urinary tract with E. coli, K. pneumoniae & P. mirabilis 1 Low number tested; less statistical validity. *NA-All other sources: For cefazolin, the % sensitive can only be ascertained on isolates E. coli, Note A: Rifampin should not be used alone for antimicrobial therapy. K. pneumoniae & P. mirabilis from uncomplicated UTIs. The cefazolin threshold Note B: Linezolid reported on critical isolates of -resistant Staphylococcus for sensitive is <= 2 µg/ml for all other sources and Enterobacteriaceae. The lowest dilution aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) only. for cefazolin on the Vitek card is 4 µg/ml, thus no sensitive results can be determined by this method.